Study Investigates COVID-19 Mortality, Early Indicators of Poor Prognosis
As COVID-19 continues to spread, and the death toll rises, experts aim to better understand the clinical features of the disease and factors for increased mortality.
DEA Deschedules Antiepileptic CBD Oral Solution Epidiolex
Cannabidiol oral solution (Epidiolex, GW Pharmaceuticals) is no longer considered a controlled substance.
Incyte, Novartis Plan Phase 3 Trial for Ruxolitinib in COVID-19
The study will evaluate ruxolitinib (Jakavi) for the treatment of COVID-19-associated cytokine storm.
FDA OKs Ixekizumab for Pediatric Patients with Plaque Psoriasis
Officials with the FDA have granted approval to ixekizumab (Taltz, Eli Lilly) injection, 80 mg/mL for the treatment of pediatric patients with moderate-to-severe plaque psoriasis.
FDA Approves Luspatercept-aamt for Anemia in Lower-Risk Myelodysplastic Syndromes
Officials with the FDA have approved luspatercept-aamt (Reblozyl, Bristol Myers Squibb and Acceleron Pharma) for the treatment of anemia in adults with lower-risk myelodysplastic syndromes.
FDA OKs Treatment for Hemophilia A or B with Inhibitors
Coagulation factor VIIa (recombinant)-jncw (Sevenfact, LBF) contains an active ingredient from a genetically engineered animal.
Rimegepant Demonstrates Efficacy in Prevention of Migraine
Rimegepant (Nurtec ODT, Biohaven Pharmaceuticals) reduced monthly migraine days in patients with episode and chronic migraine in a clinical trial.
Clinical Trial Tests Efficacy of Short-Acting GLP-1 Receptor Agonist in Type 1 Diabetes
A clinical trial funded by AstraZeneca evaluated the use of short-acting GLP-1 receptor agonists as an add-on treatment to insulin therapy in type 1 diabetes.
What Is Disseminated Zoster?
Less common but more communicable than localized zoster
Ticagrelor Monotherapy Shows Cardiovascular Benefit in Patients with Diabetes
Ticagrelor alone, without aspirin, reduced bleeding without increasing the cardiovascular risks.
FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer
Officials with the FDA have approved durvalumab (Imfinzi) for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), in combination with standard-of-care (SoC) chemotherapies, in adult patients.
Alirocumab Evaluated for Treatment of Homozygous Familial Hypercholesterolemia
Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data.
FDA Permits Emergency Use of Experimental Treatments for COVID-19
Chloroquine and hydroxychloroquine have been authorized to treat hospitalized patients with COVID-19.
FDA Approves Ozanimod for Relapsing Multiple Sclerosis
Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
Study Examines Wide Range of Potential Influenza-Related Complications
Health care providers should look out for more than just respiratory diagnoses in patients when it comes to influenza-associated complications, according to a recent study.
New Treatment Approach Proposed for Respiratory Distress in COVID-19
Tissue plasminogen activator, which is used to treat blood clots, may help severely ill patients with COVID-19 who are in respiratory failure, according to a new paper.
Lopinavir-Ritonavir Shows No Substantial Benefit for Patients with COVID-19
A study investigated the use of lopinavir-ritonavir for the potential treatment of hospitalized patients with severe COVID-19.
Phase 3 Trial of Gefapixant Shows Favorable Efficacy Results for Chronic Cough Treatment
The trials demonstrated a significant decrease in 24-hour coughs per hour versus placebo at 12 and 24 weeks.
FDA OKs Crisaborole for Use in Children as Young as 3 Months of Age
Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.
Study Findings Support Scaling Up PrEP Use in the US to Fight HIV
Increases in PrEP coverage were associated with reductions in HIV infections, a new study found.
Abrocitinib Improves Moderate-to-Severe Atopic Dermatitis in Phase 3 Study
Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.
Phase 3 Trial to Evaluate Tocilizumab for Severe COVID-19 Pneumonia
Genentech is launching a phase 3 clinical trial evaluating tocilizumab (Actemra) plus standard of care for use in hospitalized adult patients with severe COVID-19 pneumonia.
CDC: Early Data Show Younger Adults Not Spared from Coronavirus Risks
A CDC analysis of preliminary data suggests that COVID-19 complications can occur in adults of any age.
Analysis Shows Potential Targets for Immune Responses to Novel Coronavirus
A study identified significant similarities between SARS-CoV and SARS-CoV-2.
NASH Drug Pipeline Shows Promise
Analysts have forecasted the market for NASH drugs could reach $20 billion by 2025.
Study Suggests Digestive Symptoms May Be Associated with COVID-19
A recent study from China found that diarrhea was a prominent symptom among up to half of patients with COVID-19 during the outbreak in Wuhan.
COVID-19 May Remain Detectable on Surfaces, in Aerosols for Several Hours
A study evaluated the stability of COVID-19 compared with SARS-CoV-1.
Ubrogepant: A Novel Drug Mechanism for Migraine Treatment
On December 23, 2019, the FDA approved ubrogepant for the acute treatment of migraine with and without aura in adult patients.
Clinical Trials of Sarilumab to Treat Severe COVID-19 Set to Begin in the US
Sarilumab is currently used to treat adult patients with moderately-to-severely active rheumatoid arthritis after treatment with at least 1 disease-modifying antirheumatic drug.
Clinical Trial Launched for Investigational COVID-19 Vaccine
A clinical trial evaluating an investigational vaccine for the 2019 novel coronavirus, SARS-CoV-2, has been launched, with volunteers receiving the first injection on March 16.
